AstraZeneca to buy China's Gracell Biotechnologies in $1.2 bilion Deal
Selasa, 26 Desember 2023 | 20:36 WIB
KONTAN.CO.ID - REUTERS - AstraZeneca AZN.L said on Tuesday it will buy Gracell Biotechnologies GRCL.O for up to $1.2 billion as the Anglo-Swedish pharma company furthers its cell therapy ambitions and boosts its presence in China, the world's second-largest pharmaceuticals market.
The cash deal, which adds several experimental therapies to AstraZeneca's portfolio, values Gracell at $2 per ordinary share, or $10 per American Depository Share, of Gracell, representing a premium of 61.6% from its last close on Dec. 22.
Ini Artikel Spesial
Agar bisa lanjut membaca sampai tuntas artikel ini, pastikan Anda sudah berlangganan.
Sudah Berlangganan? Masuk
Berlangganan dengan Google
Gratis uji coba 7 hari pertama dan gunakan akun Google sebagai metode pembayaran.
Business Insight
Artikel pilihan editor Kontan yang menyajikan analisis mendalam, didukung data dan investigasi.
Kontan Digital Premium Access
Paket bundling Kontan berisi Business Insight, e-paper harian dan tabloid serta arsip e-paper selama 30 hari.
Masuk untuk Melanjutkan Proses Berlangganan
